Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Xtx501

Preclinical

XXilio Development, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic NSCLC - Non-Small Cell Lung CancerNot yet recruiting

Metastatic NSCLC - Non-Small Cell Lung CancerPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalNot yet recruiting

Metastatic NSCLC - Non-Small Cell Lung Cancer

NCT07688577

Clinical

Trials by Indication[1]

Metastatic NSCLC - Non-Small Cell Lung Cancer1 trial

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX501 in Participants With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Not yet recruiting·XXilio Development, Inc.·Preclinical·NCT07688577·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xtx501. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Xtx501. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xilio Development, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: XXilio Development, Inc.

Related News